Personalis, which provides a genome sequencing platform for cancer research, filed on Thursday with the SEC to raise up to $115 million in an initial public offering.
The Menlo Park, CA-based company was founded in 2011 and booked $48 million in sales for the 12 months ended March 31, 2019. It plans to list on the Nasdaq under the symbol PSNL. Personalis filed confidentially on March 27, 2019. Morgan Stanley, BofA Merrill Lynch and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
